Table 4 Correlation of SF-12 scores according to demographic and clinical factors. Significant p levels (<0.05) are in bold.
From: Quality of life analysis after stereotactic radiofrequency ablation of liver tumors
n | PCS Median (IQR) | p | n | MCS Median (IQR) | p | |
|---|---|---|---|---|---|---|
Total | 337 | 46.6 (39.1–53.5) | 337 | 53.2 (47.1–57.9) | ||
Sex | 0.077 | 0. 012* | ||||
Male | 244 | 46.9 (40.8–54.0) | 244 | 53.5 (47.8–58.0) | ||
Female | 93 | 43.5 (35.8–52.7) | 93 | 52.2 (42.1–57.0) | ||
Age | 0.140 | 0.644 | ||||
≤ 40 | 18 | 36.8 (34.2–50.2) | 18 | 53.6 (45.6–60.3) | ||
41–50 | 27 | 46.9 (39.4–55.2) | 27 | 53.7 (43.6–58.4) | ||
51–60 | 79 | 47.1 (42.4–54.8) | 79 | 53.4 (49.6–57.9) | ||
61–70 | 117 | 45.9 (39.1–53.4) | 117 | 52.9 (46.7–57.8) | ||
> 70 | 96 | 46.4 (37.9–52.2) | 96 | 53.3 (45.2–57.7) | ||
Cirrhosis | 0.807 | 0.539 | ||||
Yes | 123 | 46.6 (40.2–52.3) | 123 | 53.4 (47.8–58.3) | ||
No | 211 | 46.8 (38.9–54.6) | 211 | 53.2 (46.5–57.8) | ||
Tumor type | 0.331 | 0.538 | ||||
HCC | 145 | 47.0 (41.7–54.2) | 45 | 52.9 (47.1–57.9) | ||
CCC | 25 | 42.2 (36.8–55.5) | 6 | 54.7 (46.2–57.9) | ||
Metastases | 159 | 45.9 (38.1–53.4) | 58 | 53.4 (47.1–57.8) | ||
Benign | 7 | 37.1 (34.3–48.4) | 7 | 51.0 (40.7–60.2) | ||
Tumor size | 0.191 | 0.680 | ||||
< 3 cm | 182 | 46.9 (41.4–53.4) | 182 | 53.5 (47.1–57.8) | ||
> 3 cm | 151 | 44.3 (37.7–54.1) | 151 | 52.7 (46.4–58.1) | ||
Tumor number | 0.315 | 0.390 | ||||
n = 1 | 182 | 46.9 (40.7–53.5) | 182 | 53.7 (47.2–58.1) | ||
n > 1 | 152 | 44.3 (38.1–54.5) | 152 | 52.8 (47.0–57.8) | ||
Pain after RFA | 0.000* | 0.090 | ||||
Present | 180 | 43.2 (36.2–50.7) | 180 | 52.5 (45.7–57.5) | ||
Absent | 157 | 48.6 (42.6–55.3) | 157 | 54.0 (48.5–58.1) | ||
Complications | 0.005* | 0.317 | ||||
Present | 29 | 40.6 (33.1–47.5) | 29 | 49.6 (40.2–60.1) | ||
Absent | 307 | 46.9 (40.0–54.6) | 307 | 53.3 (47.2–57.8) | ||
Redo RFA | 0.009* | 0.011* | ||||
Yes | 330 | 46.9 (39.5–53.5) | 330 | 53.3 (47.2–57.9) | ||
No | 7 | 32.8 (30.2–39.2) | 7 | 42.6 (38.8–50.8) |
